stockrow
Friday 6 November 2026
Export ELVN’s income statement to Excel — free account
Enliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −8.34%
Quarter to June 2026, against a year earlier
49.25
4.46
+9.96%
Follow ELVN
Alert me
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
12.38 | 4.21 | 7.29 | 14.47 | 12.86 | 8.00 | 10.28 | 19.99 | 28.66 |
Net Debt/EBITDA |
0.00 | 0.00 | 1.20 | 2.13 | 1.76 | 1.96 | 2.88 | 3.02 | 3.87 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.04) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.00 | 0.77 | 0.93 | 0.76 | 0.91 | 0.85 | 0.86 | 0.82 | 0.68 |
Capex/Depreciation |
— | — | (10.00) | (0.08) | (0.05) | (2.85) | 0.03 | (0.06) | 1.53 |
| 0.00% | 54.18% | 62.43% | (276.61%) | (60.29%) | (818.29%) | (84.67%) | (32.04%) | (26.95%) | |
| 0.00% | (294.28%) | (114.45%) | (79.29%) | (55.70%) | (42.57%) | (40.31%) | (29.79%) | (25.86%) | |
ROIC |
0.00% | 0.00% | (167,472.22%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
0.00% | (193.04%) | (87.33%) | (58.24%) | (59.93%) | (54.64%) | (29.70%) | (29.41%) | (22.62%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.51) | (2.03) | (125.38) | (10.75) | (8.64) | (10.46) | (1.73) | (1.56) | (1.24) |
Cash per Share |
0.56 | 1.71 | 164.62 | 25.34 | 16.67 | 24.18 | 7.12 | 6.66 | 8.16 |
Shareholders Equity per Share |
(0.90) | (6.09) | 164.67 | 24.25 | 15.89 | 23.34 | 6.92 | 6.58 | 8.11 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.90) | (6.09) | 164.67 | 24.25 | 15.89 | 23.34 | 6.92 | 6.58 | 8.11 |
Free Cash Flow |
(8.78) | (8.78) | (22.02) | (37.42) | (46.78) | (32.69) | (61.42) | (73.24) | (70.25) |
Working Capital |
9.40 | 5.87 | 26.43 | 84.16 | 85.49 | 68.04 | 240.26 | 302.21 | 458.31 |
Capital Expenditures |
— | — | (0.14) | (0.02) | (0.01) | (0.61) | (0.15) | (0.04) | 0.06 |
Net Current Asset Value |
8.74 | 5.87 | 26.24 | 84.00 | 85.08 | 67.38 | 240.19 | 302.21 | 458.31 |
| Other line items | |||||||||
Quick Ratio |
11.71 | 4.03 | 6.89 | 14.12 | 12.52 | 7.78 | 9.78 | 19.70 | 27.92 |
Depreciation/Fixed assets |
— | — | 0.03 | 0.63 | 1.02 | 0.24 | (5.80) | 1.62 | 1.06 |
Cash ROIC |
168.84% | 46.36% | (38.08%) | (21.67%) | (26.53%) | (22.02%) | (12.31%) | (11.75%) | (7.62%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.51) | (2.03) | (124.58) | (10.74) | (8.64) | (10.27) | (1.72) | (1.55) | (1.24) |
Capex per Share |
0.00 | 0.00 | (0.80) | (0.01) | 0.00 | (0.20) | 0.00 | 0.00 | 0.00 |
Average Payables |
0.67 | 0.67 | 1.28 | 1.81 | 2.17 | 2.90 | 1.99 | 0.94 | 1.75 |
Average Assets |
8.96 | 3.85 | 20.50 | 62.07 | 92.24 | 88.47 | 177.58 | 298.81 | 400.96 |
Average Common Equity |
(20.92) | (20.92) | (37.58) | 17.79 | 85.23 | 4.60 | 84.54 | 277.88 | 384.72 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates